Transcriptional control of p53 expression participates in the generation of appropriate levels of active p53 in response to mitogenic stimulation. This prompted us to study the role of a putative AP-1 and a NF-kB motif in the human p53 promoter for transcriptional regulation. We show that mutation of the AP-1 or the NF-kB motif abolishes transcription from the human p53 promoter in HeLa, HepG2 and adenovirus type 5 E1-transformed 293 cells. In comparison, mutation of the previously characterized Myc/Max/USF binding site in the human p53 promoter reduces the transcription rate ®vefold. The AP-1 motif in the human p53 promoter binds c-Fos and c-Jun and the NF-kB motif binds p50 NF-kB1 and p65 RelA . The cooperative nature of transcriptional activation by these factors was documented by repression of c-fos or NF-kB1 translation: Pretreatment of the cells with a cfos or p50 NF-kB1 antisense oligonucleotide suppresses transcription from the human p53 promoter completely. In addition, we show that (a) the level of endogenous p53 mRNA and (b) transcription from the strictly p53-dependent human mdm2 promoter are reduced in the presence of c-fos, c-jun, p50 NF-kB1 , p65 RelA or c-myc antisense oligonucleotides, underscoring the importance of these transcription factors for the expression of functional p53.
Introduction
The tumor suppressor p53 plays a pivotal role for the fate of a cell since it prevents cell cycle progression or induces apoptosis when cells are exposed to genotoxic or hypoxic stress or suboptimal growth conditions (for review, see Soussi et al., 1994 and Hansen and Oren, 1997) . Its misfunction is associated with many tumor incidences in human.
p53 was found to function as a transcriptional regulator of several cellular genes: It transactivates genes like GADD45 (Kastan et al., 1992) , p21 , MDM2 (Perry et al., 1993; Chen et al., 1994) , bax (Miyashita and Reed, 1995) and cyclin G (Okamoto and Beach, 1994) and transrepresses TATAmediated transcription (Mack et al., 1993) of genes such as PCNA and several viral promoters Deb et al., 1992) . Both, the expression and the activity of the p53 protein are tightly controlled. One example for the regulation of p53 activity at the protein level is the Mdm2-mediated feedback loop: p53 transactivates transcription of mdm-2, and Mdm-2 binds to and thereby masks the N-terminal transactivation domain of p53 (Wu et al., 1993; Oliner et al., 1993) . Another example is the repression of p53 activity by viral oncoproteins from DNA tumorviruses: In order to replicate in quiescent cells, these DNA tumorviruses require induction of cell growth to activate cellular factors essential for viral DNA replication. To prevent upregulation of active p53 in these cells, the latter is either degraded (e.g. induced by the E6 protein of HPV 18) or inactivated (e.g by functions of E1B of adenoviruses; for review see Shen and Shenk, 1995 and Teodoro and Branton, 1997) .
In addition, control of p53 at the transcriptional level plays an important role in mitogenic stimulation or induced dierentiation (Reich and Levine, 1984; Balint and Reisman, 1996) . Moreover, expression rates of mutant or wild type p53 in tumors can be altered by deregulated p53 transcription (Soini et al., 1992) . To understand the mechanisms that control human p53 transcription, we have analysed the role of a putative AP-1 motif for the regulation of transcription from the human p53 promoter in context with that of the NFkB, NF-1 and Myc/Max/USF motifs in the vicinity of the transcriptional start region (TSR, see Figure 1 ).
We show that the AP-1 and the NF-kB motif are, beside the Myc/Max/USF-binding motif, required for ecient transcription from the hp53 promoter and bind at least c-Jun/c-Fos (AP-1 motif) and p50 NF-kB1 /p65 RelA (NF-kB motif). Moreover, we provide evidence that cJun, c-Fos p50 , p65 RelA and c-Myc are important for the expression of functional endogenous p53.
Results

Comparison of the human and mouse p53 promoters
The human (h)p53 promoter diers from the mouse p53 promoter in several instances, although some binding motifs for transcription factors are highly homologue. One striking dierence is the position of the transcriptional start sites: The human promoter contains one prominent start region (TSR; Figure 1 ) around position 7114 (with respect to the end of the untranslated exon 1 (Tuck and Crawford, 1989) , whereas the mouse promoter has three dominant start positions, indicated as TS+1, TS+61, and TS+105 in Figure 1 (Bienz- Tadmor et al., 1985) .
The promoter of the mouse p53-gene has been studied in some detail and binding motifs for several transcription factors were found, including PF-1 and an NF-1-like binding factor at the`+1' transcription initiation site (Ginsberg et al., 1990) , as well as sites for NF-kB (Wu and Lozano, 1994) , an E-box that binds USF (Reisman and Rotter, 1993) and Myc/ Max (Ronen et al., 1991) plus additional motifs that mediate positive or negative transcriptional regulation (Roy and Reisman, 1996) . The Myc/Max/USF motif in the hp53 promoter was shown to be a target for elevated Myc/Max-mediated p53 expression, although activation by USF might play a role for transactivation, dependent on the cell line examined (Roy et al., 1994) . The NF-kB-motif in the human promoter shares high homology with that in the mouse but they are not identical (Figure 1 ). In addition, a putative AP-1 motif with high homology to the mouse PF-1 site exists in the hp53 promoter. The mouse p53 protein was found to regulate its own expression by transactivating p53-transcription through a motif that integrates the NF-kB motif (Dee et al., 1993) , although both the human and the mouse p53-motif share little homology with the p53-consensus sequence for p53 binding motifs (elDeiry et al., 1992) .
The AP-1 and the NF-kB motif are indispensible for ecient transcription from the human p53-promoter in several cell lines and bind c-Fos/c-Jun or p50 NF-kB1 / p65 RelA , respectively
To examine the role of the AP-1 motif for the regulation of transcription from the hp53 promoter in context with that of the NF-kB, the NF-1/YY-1 and the Myc/Max/USF motif, we analysed the transcriptional activation potential of the respective promoter constructs (Figure 2a ) in comparison with the wild type promoter region from 7317 to 765 (with respect to the end of exon 1) in transient Luciferase expression assays.
HeLa tk 7 cells were serum starved (0.5% FCS, 48 h) or treated with TPA for 36 h after serum starvation, which resulted in a ®vefold increase in transcription in HeLa tk 7 cells (Figure 2b ). This corresponds well with the induction of endogenous p53 protein as judged from Western blots with nuclear extracts from TPAtreated and -untreated HeLa tk 7 cells that can be detected in 50 mg of nuclear extracts after overnight exposure (Figure 2b, insertion) , despite the p53-degrading activity of intrinsic HPV 18 E6 (Schener et al., 1990 , Butz et al., 1995 .
Interestingly, the transcription was abolished when either the AP-1 motif (mutant M1) or the NF-kB motif (mutant M3) were mutated (Figure 2b ). The small activation of transcription in case of M1 and M3 upon treatment of the cells with TPA (to about 3% of the hp53-wt promoter) was in the range of the pGL2b control plasmid. Thus, both motifs are indispensable for the transcription from the hp53 promoter, which implies cooperative action of the respective transcription factors that bind to these sites. When the YY-1/ NF-1 motif was mutated (mutant M2), transcription was reduced about threefold in untreated and about twofold in TPA-treated cells (Figure 2b) . A ®vefold reduction of transcription was observed when the Myc/ Max/USF binding site was mutated (Figure 2b ). This corresponds with data from others concerning the role of the YY-1/NF-1 (Furlong et al., 1996) or the Myc/ Max/USF motif (Roy et al., 1994) in transactivation from the hp53 promoter.
Due to the reported autoregulation in case of the mouse p53 promoter through sequences that overlap with the NF-kB motif (Dee et al., 1993) , we had ®rst chosen HeLa tk 7 cells, since HeLa they were reported to contain low levels of the p53-protein caused by HPV-E6-mediated degradation of p53 (Schener et al., 1990 , Butz et al., 1995 . To con®rm our results in cells that are free from viral sequences and express p53 wt, we examined transcription from the hp53-promoter in exponentially growing HepG2 hepatoma cells (Bressac et al., 1990; Puisieux et al., 1993; Ho et al., 1996; Jiang et al., 1996) . As for HeLa cells, transcription from the hp53 promoter was suppressed to nearly control levels when the AP-1 or the NF-kB motif was mutated (M1 and M3, respectively; Figure 2c ) and reduced about threefold upon mutation of the Myc/Max/USF motif (M4, Figure 2c ). In contrast to the ®ndings with HeLa cells (Figure 2b ), transcription remained unaltered when the YY-1/NF-1 motif was mutated (M2, Figure  2c ).
Stabilization of p53 by E1A in E1-transformed cell lines induces apoptosis that is prevented by functions of the adenoviral 19 kD and the 55 kD E1B proteins (Lowe and Ruley, 1993; Debbas and White, 1993) . Functions of E1A may contribute to the high levels of p53 in these cells (Furlong et al., 1996) . We therefore examined whether E1A functions in exponentially growing 293 cells that are transformed by expression of the E1 region from Adenovirus type 5 might alter the strong reduction of transcription from the p53 promoter upon mutation of the AP-1, NF-kB, and Myc/Max/USF motifs. However, mutation of the AP-1 (M1), NF-kB (M3) or the Myc/Max/USF (M4) motif repressed transcription in 293 cells too, although to a Figure 2b and c, respectively). Thus, the cisactivating functions of the AP-1, the NF-kB, and the Myc/Max/ USF motif are important for ecient transcription from the hp53 promoter, even in the presence of E1A. To con®rm our ®ndings, we suppressed the expression of c-Fos or of p50 in HeLa, HepG2 and in 293 cells by pretreatment of the cells with 5 nmol/ml of a c-fos or a p50 NF-kB1 antisense oligonucleotide in comparison with a p53 antisense oligonucleotide (Figure 2e ). In all cell lines, the c-Fos as well as the p50 NF-kB1 , but not the p53 antisense oligonucleotide nearly abolished the transcription from the hp53 (wt) promoter. This indicates that, independent from the expression of p53 or adenoviral E1 proteins, c-Fos and p50 NF-kB1 are, either directly or indirectly, e.g. via c-Fos-or p50 NF-kB1 -transactivated proteins, mandatory for the ecient transcription from the hp53 promoter. Second, the hp53 promoter does not seem to be autoregulated, since a reduction of transcription after pretreatment of the cells with p53 antisense oligonucleotides was not detected in HepG2 cells that express p53 wt (Bressac et al., 1990; Puisieux et al., 1993; Ho et al., 1996; Jiang et al., 1996) .
The hp53 promoter was shown to be transactivated by expression of c-Myc (Roy et al., 1994) , although a contribution of the USF transcription factor that transactivates the mouse p53 promoter (Reisman and Rotter, 1993) may not be excluded. We therefore analysed how cotransfections of c-Myc and/or USF expression constructs (pZip-Myc or pCX-USF, respectively) modulate transcription from the hp53-promoter ( Figure 2f ). For these experiments p53 wt-expressing HepG2 cells were chosen, since mutant p53 was recently shown to be a potent transactivator of c-myc gene expression (Frazier et al., 1998) and vice versa (Roy et al., 1994) . We found that the hp53 promoter was only moderately (up to twofold) activated by cotransfection with 50 ± 500 ng of pCX-USF, whereas addition of 50 ± 100 ng of pZip-Myc enhanced transcription up to 11-fold, respectively ( Figure 2f ). This corresponds with the results from others, who show that sequestration of Myc/Max transactivating complexes from the hp53 promoter strongly represses transcription of the reporter gene, indicating a prominent role for Myc/Max in transactivation of the hp53 (Roy et al., 1994) .
To examine which transcription factors bind to the putative AP-1 and NF-kB motifs, we analysed the binding of nuclear proteins to these motifs in gel retardation assays. The putative AP-1 binding site in the hp53 promoter (TGACTCT) resembles thè classical' AP-1 binding TRE-element in the human f e Figure 2 The AP-1, the NF-kB and the Myc/Max/USF motif cooperate in the activation of transcription from the human p53-promoter (a) Schematic presentation of the hp53 promoter constructs used in transient Luciferase reporter expression experiments. M1 lacks the AP-1 motif, in M2 the YY-1/NF1, in M3 the NF-kB, and in M4 the Myc/Max/USF motifs were mutated as described in the Materials and methods section; (b) HeLa tk 7 cells were transfected with 0.5 mg of either the hp53-wild type (wt) or the M1 ± M4 mutant promoter constructs and treated 8 h later with (+TPA) or without (7TPA) TPA for 32 h. Cytoplasmic extracts were assayed for Luciferase activity 40 h after removal of the DNA-Lipofectamin TM complex. The Luciferase activity of the TPA-induced wild type construct was set to 100%. Standard deviations of triple experiments are shown; Insertion: Overnight-exposure of a chemiluminescence detected (Pierce) Western blot showing the expression of p53 in 50 mg of nuclear extract from untreated and TPA treated HeLa cells; (c and d) Transient Luciferase expression experiments as described in (a) but with exponentially growing (medium contained 10% FCS) HepG2 (c) or 293 (d) cells; (e) Transcription from the hp53 promoter in the presence of p50 NF-kB1 cfos and p53 antisense (AS) oligonucleotides: Exponentially growing HeLa, HepG2 and 293 cells were preincubated for 16 h with 5 nmol/ml of the respective antisense oligonucleotides and transfected as described in the Materials and methods section leaving the cells in DMEM/10% FCS; (Luciferase expression levels are given in arti®cial [luminometer] units per 10 mg of cell extract). The results shown represent a mean of transfections in triplicate; sd was less than 10% in all cases. (f) Transcription from the hp53 promoter after cotransfection of HepG2 cells with the p53-promoter construct and 50-500 ng of pCX-USF or 50-100 ng of pZipMyc expression plasmids as described in the Materials and methods section collagenase promoter (coll-TRE: TGAGTCA). We therefore examined binding of nuclear proteins from HeLa tk 7 cells to the p53-AP-1 motif in comparison with the coll-TRE in gel retardation assays after antibody perturbation with anti c-Fos or anti c-Jun antibodies ( Figure 3 ). Prior to the preparation of the nuclear extracts, the HeLa tk 7 cells were treated with TPA for 24 h to activate the AP-1 (Lee et al., 1987 , Angel et al., 1987 , Lamph et al., 1988 and NF-kB (Sen and Baltimore, 1986, Bohnlein et al., 1988) transcription factors. Up to ®ve shifted complexes appeared in case of the putative AP-1 motif from the hp53-promoter (complexes`a ± e' in Figure 3a) . The slowest migrating complex (`a') was abolished in the presence of an anti c-Fos antibody and the same complex was supershifted by an anti c-Jun antibody (Figure 3a) . In addition to the c-Jun/c-Fos complex, formation of other, yet unidenti®ed complexes (labeled as`b ± e' in Figure 3a ) was observed. Complexes`b' and`c' are speci®c, since their formation was prevented in the presence of a 1006molar excess of the unlabeled AP-1 motif oligonucleotide (Figure 3b ; complexes`d' and`e' seem to be non speci®c, since their formation was not reproducible). The shifting pattern found with the hp53 promoter resembles that obtained with the TREelement from the human collagenase promoter (Figure 3c , Angel et al., 1987) . Although binding of other factors, namely ATF-2 (Hagmeyer et al., 1993) and/or ATF-3 (Hagmeyer et al., 1996) to the AP-1 motif might be suggested, we have no indication for the binding of these factors (data not shown).
The NF-kB motif was found to bind three complexes (`a ± c' in Figure 4a ) in gel retardation assays: Formation of complex`a' was diminished and of complex`b' was prevented when an anti NF-kB1 (p50 NF-kB1 ) antibody was used in antibody perturbation experiments ( Figure 4a ) while a supershifted complex (`s') appeared. Complex`b' was slightly aected by an anti p65-(RelA) antibody, but formation of complex`a' was nearly prevented (Figure 4a ). From these data we conclude that complex`b' most likely represents the p50 NF-kB1 /p50 NF-kB1 homodimer and complex`a' the p50 NF-kB1 /p65 RelA heterodimer, whereas the nature of complex`c' remains unclear. However, all complexes are speci®c, as judged from competition experiments with the unlabeled oligonucleotide (Figure 4b ). In contrast, an oligonucleotide with a mutated NF-kB binding sequence (TGGGTTTTCCCC was mutated to TGAGTTTGACCC) was unable to compete for the binding (Figure 4b) .
From these data, we conclude that c-Fos/c-Jun and p50 NF-kB1 /p65 RelA participate in the cooperative transcription from the hp53 promoter, although the contribution of other factors of the AP-1/ATF and Rel-families cannot be excluded.
Expression of endogenous p53 is repressed by AP-1, NF-kB and c-Myc antisense oligonucleotides
We next examined the role of the p65 RelA , p50 NF-kB1 , cFos, c-Jun and c-Myc transcription factors for the expression of endogenous p53. The expression of p65 RelA , p50 NF-kB1 , c-Fos, c-Jun and c-Myc is reduced in WCE from HepG2 cells that were treated with the respective phosphorothioate-antisense oligonucleotides (see Materials and methods). In case of the p50 antisense treatment, the expression of the p105 NF-kB1 precursor protein was also reduced (Figure 5a ).
We next isolated total RNA from the antisense treated HepG2 cells and performed a semiquantitative RT ± PCR with speci®c p53-plus G3DPH-primer pairs, the latter serving as an internal control (Figure 5b ). The PCR products were analysed on 1.5% AgaroseEthidiumbromide gels (where the levels of the PCR products analysed were adjusted to equal amounts of the G3DPH PCR product; Figure 5b ). In all cases of antisense treatment the level of p53 RT ± PCR product and thus expressed p53 RNA was reduced as compared with untreated HepG2 cells, although the reduction was higher in case of p50 NF-kB1 and p65 RelA than for c-fos and c-jun antisense oligonucleotides. In case of c-myc antisense treatment, the expression of endogenous p53 was reduced most, which might be due to a more ecient reduction of c-Myc by the c-myc antisense oligonucleotide due to the high turnover rate of the cMyc protein (Figure 5b) .
Thus, reduction of p65 RelA , p50 NF-kB1 , c-Fos, c-Jun and c-myc expression leads to reduced synthesis of endogenous human p53 in HepG2 cells, arguing for an important role of these transcription factors in the control of endogenous p53 expression.
When the in¯uence of antisense treatment was assayed at the protein level, the amount of the p53 protein was signi®cantly reduced in HepG2 and 293 cells that had been treated with the c-fos antisense oligonucleotide, indicating that c-Fos is crucial for human p53 expression under these conditions ( Figure  5c ). In case of the p50 NF-kB1 antisense oligonucleotide expression of endogenous p53 was reduced in 293 but not in HepG2 cells (Figure 5c ), despite the reduction of transcription from the hp53 promoter or the endogenous p53 mRNA level by the p50 NF-kB1 antisense oligonucleotide (Figures 2e and 5b, respectively) . However, a medium reduction (2 ± 3-fold) might not be easily detected in Western blot experiments.
We therefore determined the amount of transcriptionally active p53 in antisense treated HepG2 cells by analysing the transcription rate from the strictly p53-dependent intronic mdm2 promoter. This promoter contains two p53 responsive elements (p53-RE1 and p53-RE2, respectively; Figure 6a , inserted box), where p53-RE1 represents the dominant motif that is essential for ecient transcriptional activation (Zauberman et al., 1995) . We ®rst show that transactivation of this promoter in growing HepG2 cells is, too, strictly dependent on the presence of p53, since both deletion of p53-RE1 (mdm2m in Figure 6a ) and pretreatment of the cells with the p53 antisense oligonucleotide eciently reduced transcription from the mdm2 promoter (Figure 6a ). Pretreatment of HepG2 cells for 16 h with 5 nmol/ml of c-fos, c-jun, p50 NF-kB1 , and p65 RelA , antisense oligonucleotides prior to transfection with the mdm2 promoter construct resulted in about a threefold reduction of transcription in case of c-jun and c-fos antisense oligonucleotide, and about a twofold reduction in case of the p50 NF-kB1 and the p65 RelA antisense oligonucleotide (Figure 6b ). When the cells were treated with the c-myc antisense oligonucleotide, a more than ®vefold reduction of transcription was observed (Figure 6b ). The eects of the antisense oligonucleotides may not be compared in a quantitative manner, due to biological determinants as dierent antisense oligonucleotide eectivity or dierent halflives of the respective target mRNA's and/or expressed proteins. Nevertheless these data document the importance of transcriptional activation from the hp53 promoter by c-Fos, c-Jun, p50 NF-kB1 , p65 RelA , and c-Myc for the expression of transcriptionally active endogenous p53 in growing cells.
Discussion p53, as a guardian of genomic stability and cell growth, functions as a potent inhibitor of cell cycle progression or as an inducer of apoptosis. It is, therefore, tightly controlled at the post-translational, post-transcriptional and transcriptional level (reviewed in: Hansen and Oren, 1997). The study of transcription from the human p53 promoter is of interest for tumor biology, since, in some tumors, it participates in the enhanced expression of mutant p53 (Balint and Reisman, 1996) or the reduced expression of wt p53 (Soini et al., 1992) . In addition, transcriptional regulation participates in the p53-mediated control of mitogenic stimulation and induced dierentiation (Reich and Levine, 1984) as well as in the response to genotoxic stress (Sun et al., 1995) .
We show here that a Fos/Jun-binding AP-1 motif and the NF-kB motif that binds p50 NF-kB1 /p65 RelA are, beside Myc/Max (Roy et al., 1994) , essential for ecient transcription from the hp53 promoter under normal growth conditions or after TPA treatment in HeLa, 293 or HepG2 cells. The NF1/YY-1 motif, too, contributes to the activation of transcription, although its participation seems to be dependent on the cell line used (Furlong et al., 1996 and this paper).
The signi®cant role of the AP-1 complex and cell type dependent participation of NF-1/YY-1 in basal (serum starved cells) and activated (10% FCS or TPAtreated cells) transcription from the hp53 promoter argues against earlier ®ndings that a minimum promoter region of 80 bp upstream from the transcriptional start site is sucient for full promoter activity, since both the AP-1 and the NF-1/YY-1 motif reside further upstream. Moreover, the ecient suppression of transcription by deletion of the AP-1 motif or the mutation of one of the other motifs documents a cooperativity in the transactivation from the hp53 promoter between AP-1, NF-kB, and Myc/Max. A transcriptional cooperativity that involves AP-1 and NF-kB has also been described for promoters of other genes like MHC class I (H-2K b , Brockmann et al., 1996) , E-Selectin (Kaszubska et al., 1993) , I-kBa (Kralova et al., 1996) , IL-8 (Yasumoto et al., 1992) and IFNb (Du W et al., 1993) , either involving direct (Stein et al., 1993) or indirect (Gerritsen et al., 1997) physical interaction of the respective transcription factors. Figure 3 Binding of nuclear proteins to the AP-1 motif in the human p53-promoter. HeLa tk 7 cells were kept in 0.5% FCS overnight and then treated with TPA for 48 h before lysis. Nuclear extracts were prepared as described in the Materials and methods section. Gel retardation assays using the AP-1-motif oligonucleotides from the human p53 (a and b) or the human collagenase promoter (c) were performed as described in the Materials and methods section; (a) the complexes formed were named (a ± e) as indicated. Antibody perturbation experiments were done using an anti-c-Fos or an anti-c-Jun supershifting antibody (KM-1;`s' indicates the supershifted band); (b) competition experiment with a 1006molar excess of the unlabeled AP-1 wild type oligonucleotide; (c) Antibody perturbation experiments as described in (a) using the AP-1-oligonucleotide from the human collagenase promoter (coll.-TRE); the complexes formed were named (`a') and (`b'), as indicated;`s' indicates the supershifted band
The reduction of transcription we observed for the Myc/Max/USF-binding site mutant (M4) of the hp53 promoter, corresponds with results from others (Roy et al., 1994) . Moreover, we show that the expression of cMyc activated the hp53 promoter 11-fold, whereas USF-expression resulted in a less than twofold activation. This corresponds with the results from others, who show that p53 mRNA expression is reduced by c-myc antisense expression and sequestration of Myc/Max transactivating complexes from the hp53 promoter strongly represses transcription of the reporter gene (Roy et al., 1994) , indicating a prominent role for Myc/Max in transactivation of the hp53 that cannot be substituted by USF. However, the role of USF for the activation of human p53 should not be underestimated: In ®rst transient luciferase expression experiments with 48 h serum starved HepG2 cells we found up to a sevenfold activation of the hp53 promoter upon cotransfection with 1 mg of the pCX-USF construct. Thus, the extent of USF-participation in the regulation of human p53 expression might be dependent on cellular growth conditions. Our hp53 promoter regulation studies with c-fos and p50 NF-kB1 antisense oligonucleotides con®rm the prominent role of these factors in transcription from the hp53 promoter, although indirect eects may not be resolved by this technique: AP-1 (c-Jun/c-Fos) was, for instance, shown to be an ecient activator of fra-2 transcription (Sonobe et al., 1995) . Nevertheless, c-Jun, c-Fos, p50 NF-kB1 , p65 RelA and c-Myc participate in the activation of transcription from the hp53 promoter in a direct or indirect manner, since treatment of the cells with the respective antisense oligonucleotides reduced (a) the expression of endogenous p53 mRNA and (b) the activity of the p53-dependent mdm2-promoter.
AP-1, NF-kB and c-Myc are responders to mitogenic stimulation through the MAP-Kinase and/ or the PKC pathways (for reviews, see Fanger et al., 1997 and Foletta, 1996) and thus, their cooperation in upregulating expression of p53 appears to be of physiological importance to control genomic stability in cycling cells.
Ecient transcription from the hp53 promoter was independent from the presence of a functional p53-protein: Transcription from the hp53 promoter was as ecient in Hep3B cells (data not shown) that do not express p53 (Farshid and Tabor, 1992) as in HepG2 cells that contain unaltered and functionally active p53 (Farshid and Tabor, 1992; Bressac et al., 1990; Puisieux et al., 1993; Ho et al., 1996; Jiang et al., 1996) . In addition, treatment of growing cells with a functional antisense p53 oligonucleotide did not alter transcription as compared with the control level. In case of the murine p53 promoter, transfection of a p53 TM ' set (Clonetech) that results a 371 bp-fragment in RT ± PCR plus the G3DPH (Glyceraldehyde 3-Phosphate Dehydrogenase)`Amplimer TM ' set that results a 983 bp-fragment in RT ± PCR (as indicated). The G3PDH PCR product served as an internal control. In both cases several exons are spanned to exclude false results from ampli®ed genomic DNA sequences. PCR products were analysed on 1.5% Agarose-Ethidiumbromide gels. (c) Pelleted nuclei in the cell lysates from the c-fos and p50 NF-kB1`a ntisense' transient expression experiments (Figure 2e) were extracted by addition of 5M NaCl to give a ®nal concentration of 450 ± 500 mM NaCl for 30 min on ice. The resulting whole cell extracts (WCE) from HepG2 and 293 cells were analysed in Western blot experiments (70 mg of WCE/lane) for the expression of p53 using the anti-p53 (DO-1) monoclonal antibody. The blot was exposed (chemiluminescence detection) to X-ray ®lm for 10 min at room temperature in case of 293 cells and overnight at 48C plus additionally 1 h at room temperature in case of HepG2 cells a Figure 6 Suppression of transcriptionally active p53 by antisense oligonucleotides monitored by transient expression from the intronic human mdm2 promoter. (a) Transcription from the mdm2 and the mdm2m promoters (see inserted box for schematic presentation) in growing HepG2 cells was examined as described in the Materials and methods section. In case of the p53 antisense experiments 5 nmol/ml of the p53 antisense oligonucleotide was used; (b) cells were treated either with none (control) or with 5 nmol/ml of c-myc, c-jun, c-fos, p50 NF-kB1 , or p65 RelA , antisense or an unrelated (M13 ctrl) oligonucleotide as described in the Materials and methods section. The Luciferase activity of the control (without antisense sequences) was set to 100% b expression plasmid was found to activate its own transcription, although binding of the mouse p53 protein to its own promoter was not detected (Dee et al., 1993) . The autoactivation of mouse p53 in this case might therefore appear at high levels of exogenously expressed p53. However, in ®rst experiments, cotransfection of a p53 expressing plasmid (CMVhup53; kind gift from HW StuÈ rzbecher/W Deppert, Heinrich Pette Inst. f. Exp. Virologie, Hamburg) did not signi®cantly alter transcription from the hp53 promoter in serum starved or TPAinduced HeLa cells (data not shown).
Although no TATA box or initiator consensus sequence was found in the hp53 promoter (Tuck and Crawford, 1989) , the sequence`TAAAA', about 10 nucleotides upstream from the main transcriptional start region around 7114 (with respect to the 3'-end of exon 1), might function as a TATA box-like element with a probability of 57 ± 96% for the dierent nucleotide positions according to a weight matrix analysis of about 400 TATA-box containing promoters (Bucher, 1990) . We therefore started to examine the possible role of the TATA-box-like`TAAAA'-element for p53 transcription.
Materials and methods
Cells and culture media
HeLa tk 7 , HepG2 and 293 cells were obtained from ATCC. Cells were cultured in Dulbecco's modi®ed Eagle's medium (DMEM, Gibco ± BRL) including 10% FCS.
Preparation of nuclear extracts and whole cell extracts (WCE)
HeLa tk
7
, 293, or HepG2 cells were starved for 48 h in 0.5% FCS and subsequently treated overnight with TPA (50 ng/ml) or kept in 10% FCS. Cells were washed twice with phosphate buered saline (PBS) and lysed in buer A (20 mM HEPES, 10 mM NaCl, 0.2 mM EDTA, 2 mM EGTA, 2 mM DTT, pH 7.9). Release of nuclei was controlled by phase contrast microscopy. Nuclei were pelleted at 490% of cell lysis at 800 ± 1000 g for 10 min and washed three times with buer A containing 150 mM NaCl. Nuclear proteins were then extracted from the nuclei with 300 ml/10 7 cells of buer C (20 mM HEPES, 0.75 mM Spermidin, 0.15 mM Spermin, 0.2 mM EDTA, 2 mM EGTA, 2 mM DTT, 420 mM NaCl and 25% glycerol, pH 7.9) for 30 min at 48C by gentle agitation or stirring. Nuclear debris was then pelleted at 60 000 g for 90 min at 48C and the supernatant (clear nuclear extract) was frozen in aliquots at 7808C. In case of c-jun, cfos, p50 NF-kB1 , p65 RelA and c-myc antisense oligonucleotidetreatment, WCE were prepared from HepG2 cells by lysis of the cells in RNA-lysis buer (50 mM Tris, 140 mM NaCl, 1.5 mM MgCl 2 , 0.5% NP-40, 1 U RNAsin TM /ml, 1 mM DTT), since one half of the lysate was used for the preparation of cytoplasmic RNA. For WCE, 5M NaCl was added dropwise under stirring to one half of the lysate up to a ®nal concentration of 450 ± 500 mM and nuclei were extracted for 20 ± 30 min on ice. Cellular and nuclear debris was pelleted at 60 000 g for 90 min at 48C and the clear supernatant (WCE) was frozen in aliquots at 7808C.
Gel retardation assays
For gel retardation analysis, double stranded oligonucleotides containing the AP-1-or NF-kB-motif from the hp53-promoter were used. The sequence of the AP-1-oligonucleotide is: 5'-[G]G-AGAACCTGACTCTTGCACCCT-3' ([G] was added to the sequence for labeling purposes). The sequence of the NF-kB-oligonucleotide is: 5'-[GGG]TT-GTGGGATT-GGGGTTTTCCCCTCCCATGTG-3' and for the AP-1 control oligonucleotide (collagenase promoter) is: 5'-[GGG]TAAAGCATGAGTCAGACACCT-3'. The three 5'-G's in the latter two oligonucleotides were added for labeling purposes. Oligonucleotides were labeled by a ®ll-in labeling reaction of the 5'-GG-or GGG-overhang of the respective leading strand oligonucleotide with [ 32 P]dCTP using the Klenow polymerase (Boehringer, Mannheim, Germany). 3 ± 5 mg of nuclear extracts were incubated with 0.1 ± 0.2 ng of endlabeled oligonucleotides for 15 min at room temperature in binding buer: 10 mM Tris-HCl, 50 mM NaCl (®nal concentration of NaCl was adjusted to 150 mM NaCl), 1 mM EDTA, 1 mM DTT, 5% glycerol. Reactions included a 10006excess (with respect to the amount of oligonucleotide) of poly-dA-dT and/or poly-dI-dC as unspeci®c DNA. For antibody supershift experiments, nuclear extracts were ®rst incubated with 1 mg of anti-c-fos (`4-10'), -jun (`KM-1'), -NF-kB1 (`C19') orRelA (`C20') antibodies (all purchased from Santa Cruz Biotechnology, Inc., Heidelberg) for 15 min at room temperature and thereafter 10 000 ± 15 000 c.p.m. of labeled oligonucleotide, 10 mg BSA and the respective amount of 106binding buer were added and the mixture was incubated for additional 10 ± 15 min at room temperature. Mixtures were then applied to a 6% Polyacrylamide gel (2.75% crosslinking) and run at 1 V/mm for 2 h. Gels were dried and exposed to Biomax TM ®lm (Kodak) at 7808C for 2 ± 4 h or to XAR TM ®lm (Kodak) for 1 ± 3 days at room temperature.
Site directed mutagenesis of the hp53-promoter and cloning procedures
An upstream primer (5'-ATTAT-GGTACCGTATCTACGG-CACCAGGTCGGCGAG-3') containing a KpnI site and a downstream primer (5'-TATAAAGATCTCCAGCCCGAAC-CAAAGTGTCCCCG-3') carrying a BglII site were used to generate the`wild type' (wt) hp53 promoter by PCR, ranging from nucleotide (nt) 7317 to nt 765 with respect to the end of exon 1 of hp53 as nt 1. For the construction of the NF-1-and the NF-kB-mutant these primers as well as two complementary primers carrying mutations in the respective sites were used. For the NF-1-mutant the TGGGACTGTC CACAGC binding site for NF-1 was destroyed according to Jones et al. (1987) by changing the sequence to TAA-AAAGC. Mutation of these nucleotides was also shown to be sucient to prevent binding of YY-1 (compare Furlong et al., 1996) . In case of NF-kB the binding sequence TGGGTTTTCCCC was mutated to TGAGTTTGACCC. For the AP-1 mutant the AP-1 site was deleted by using a primer downstream from the AP-1 binding site in PCR (5'-ATTATGGTACCCCCTCCTCCCCAACTCCATTTCCT-3') carrying a KpnI site. For the MYC-mutant the CATGTGC was mutated to CTTGGAC, which destroys the consensus for the c-Myc-binding (CANNTG). The PCR-products were directionally cloned into the pGL2b Luciferase expression vector (Promega, Heidelberg). Insert-containing positive clones were identi®ed by restriction analysis and tested for correct inserts by automated sequencing using an`ALF' (automated laser¯uorescence) DNA sequencer (Pharmacia, Freiburg, Germany). The pCX-USF construct was a kind gift from Martin Eilers, Marburg (described in : Du H et al., 1993) . The pZip-Myc construct was described earlier (Zoidl et al., 1993) .
Transfection of HeLa tk 7 cells and TPA-treatment
Transfections were essentially performed as described earlier (Kirch et al., 1993) with some modi®cations: Prior to transfection, HeLa tk 7 cells were starved in DMEM/0.5% FCS for 48 h. Sixteen hours before transfections, all cells were seeded at a density of 1.5610 kept in DMEM/0.5% FCS. The DNA to be transfected (0.5 mg of the hp53 promoter and 2.0 mg of carrier plasmid [pRC-RZip]) was incubated with 6 ml Lipofectamin (Gibco) and 200 ml Optimem for 30 min at room temperature. Thereafter, 800 ml of DMEM without FCS were added and cells were incubated with this mixture for 5 h at 378C. The mixture was then removed and the cells were kept in 2 ml DMEM/0.5% FCS or 2 ml DMEM/10% FCS. In case of TPA-treatment, TPA (50 ng/ml) was added 8 h later. Cells were harvested 40 h after removal of the DNA-Lipofectamin mixture. In case of the USF/Myc expression experiments DOSPER TM (Boehringer) was used instead of Lipofectamin following the supplier's instructions. Transfection mixtures contained 100 ng of the pAdVAntage TM vector (Promega) that expresses the adenoviral VAI (Virus associated I) RNA to prevent inhibition of translation of the protein of interest (c-Myc and USF) by dsRNA-activated DAI (dsRNAactivated inhibitor; dsRNA is generated during transfection).
Antisense experiments
In case of cell treatment with antisense oligonucleotides and subsequent transfection with the hp53 promoter, 5 nmol/ml of antisense c-fos-, antisense p50 NF-kB1 -(Biognostik, GoÈ ttingen) or antisense p53-oligonucleotides (Lanza et al., 1995;  MWG-Biotech, Ebersberg: MWG antisense oligonucleotides contain two phosphorothioate nucleotides at their 5'-and 3'-ends) were added to growing cell cultures (40 ± 50% con¯uence) 8 h after seeding and 1.5 mg DNA in 50 ml of Hanks buered saline (HBS) plus 4 ml of DOSPER transfection reagent (Boehringer) in 50 ml of HBS was added 16 h later to the cultures without removal of the antisense containing medium. Cells were harvested 48 h after seeding. In case of transfections with the mdm2 or mdm2m promoter constructs (kind gift from M Oren, Israel; Zauberman et al., 1995) , 5 nmol/ml of c-fos, (Biognostik, GoÈ ttingen), p50 or p65 RelA (Sokoloski et al., 1993) c-jun (Brach et al., 1993 ) cmyc (Harel-Bellan et al., 1988 or p53 antisense (Lanza et al., 1995; MWG-Biotech, Ebersberg) oligonucleotides were added to cell cultures 16 h prior to transfection. Transfection procedure was as in case of the hp53 promoter.
Reverse transcription (RT) ± PCR
Cells were treated with or without antisense oligonucleotides as described above. Cells were lysed in RNA-lysis buer (50 mM Tris, 140 mM NaCl, 1.5 mM MgCl 2 , 0.5% NP-40, 1U RNAsin TM /ml, 1 mM DTT) and total cytoplasmic RNA was prepared on Silica-based Ion-exchange spun columns (`RNAEasy' system, Quiagen) following the supplier's instructions. RT was performed using AMV-reverse transcriptase and T 24 plus random primers (`Advantage TM RT-for-PCR', Clonetech). Duplex PCR of the respective cDNA was performed using PCR-`Ready to go TM ' beads (Pharmacia) with the p53 Amplimer TM ' set (5'-primer: CTG AGG TTG GCT CTG ACT GTA CCA CCA TCC; 3'-primer: CTC ATT -CAG CTC TCG GAA CAT CTC GAA GCG Clonetech) that results a 371 bp-fragment in PCR plus the G3DPH (Glyceraldehyde 3-Phosphate Dehydrogenase)`Amplimer TM ' set (5'-primer: TGA AGG TCG GAG TCA ACG GAT TTG GT;3'-primer:CAT GTG GGC CATGAG GTC CAC -CAT; Clonetech) that results a 983 bp-fragment in PCR. In both cases several exons are spanned to exclude false results from genomic sequences. The G3PDH PCR product served as an internal control. PCR products were quanti®ed on 1.5% Agarose gels and the synthesis of endogenous p53 RNA was monitored by adjusting the amount of analysed PCR products to equal G3DPH PCR product levels.
Cell lysis for Luciferase assays and Western blot experiments
For Luciferase assays, cells were washed twice with phosphate buered saline (PBS) and lysed in the Luciferase assay lysis buer (Promega) for 5 min at room temperature. Cells were scraped from the six wells and nuclei and cellular debris were pelleted by centrifugation at 14 000 r.p.m. in an Eppendorf centrifuge for 5 min. Cell lysates were frozen at 7808C. For a combinatorial use of cells for Luciferase assays and Western blot analysis, pelleted nuclei were extracted after determination of Luciferase activity in the cytoplasmic extract by addition of 5M NaCl to a ®nal concentration of 450 ± 500 mM NaCl. After stirring with microstirrers for 30 min on ice, cellular debris was removed by centrifugation at 20 000 g for 30 min at 48C and the supernatant that contained the combined cytoplasmic and nuclear extracts (whole cell extracts) was frozen at 7808C.
Luciferase assay
Luciferase assays were performed following the supplier's instructions (Promega; see also Alam and Cook, 1990) .
Western blot experiments
Western blot experiments were performed as recently described (Kirch et al., 1997) except SuperSignal TM chemiluminescence substrate (Pierce) was used for detection.
